Saul Kivimae
Overview
Explore the profile of Saul Kivimae including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
786
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rolig A, Rose D, McGee G, Rubas W, Kivimae S, Redmond W
J Immunother Cancer
. 2022 Apr;
10(4).
PMID: 35444059
Background: Tumor cell death caused by radiation therapy (RT) triggers antitumor immunity in part because dying cells release adjuvant factors that amplify and sustain dendritic cell and T cell responses....
2.
Miyazaki T, Maiti M, Hennessy M, Chang T, Kuo P, Addepalli M, et al.
J Immunother Cancer
. 2021 May;
9(5).
PMID: 34001523
Background: NKTR-255 is a novel polyethylene glycol-conjugate of recombinant human interleukin-15 (rhIL-15), which was designed to retain all known receptor binding interactions of the IL-15 molecule. We explored the biologic...
3.
Hennessy M, Wahba A, Felix K, Cabrera M, Segura M, Kundra V, et al.
Int J Cancer
. 2020 Nov;
148(8):1928-1937.
PMID: 33152115
Survival of patients with relapsed/refractory osteosarcoma has not improved in the last 30 years. Several immunotherapeutic approaches have shown benefit in murine osteosarcoma models, including the anti-programmed death-1 (anti-PD-1) and...
4.
Lee S, Kivimae S, Szoka F
Mol Ther Methods Clin Dev
. 2017 Oct;
7:60-73.
PMID: 29034260
New methods to produce large numbers of myeloid progenitor cells, precursors to macrophages (MΦs), by maintaining Hoxb8 transcription factor activity has reinvigorated interest in MΦ cell therapies. We generated Hoxb8-dependent...
5.
Lee S, Kivimae S, Dolor A, Szoka F
J Control Release
. 2016 Jul;
240:527-540.
PMID: 27422609
In the quest for better medicines, attention is increasingly turning to cell-based therapies. The rationale is that infused cells can provide a targeted therapy to precisely correct a complex disease...
6.
Kierstead P, Okochi H, Venditto V, Chuong T, Kivimae S, Frechet J, et al.
J Control Release
. 2015 Jun;
213:1-9.
PMID: 26093095
A variety of water-soluble polymers, when attached to a liposome, substantially increase liposome circulation half-life in animals. However, in certain conditions, liposomes modified with the most widely used polymer, polyethylene...
7.
Nguyen J, Sievers R, Motion J, Kivimae S, Fang Q, Lee R
Mol Pharm
. 2015 Feb;
12(4):1150-7.
PMID: 25642730
There is a great need for delivery strategies capable of efficiently localizing drugs to the damaged myocardium that do not require direct intramyocardial injection of therapeutic molecules. In the work...
8.
Sockolosky J, Kivimae S, Szoka F
PLoS One
. 2014 Jul;
9(7):e102566.
PMID: 25057984
We explore a strategy to substantially increase the half-life of recombinant proteins by genetic fusion to FcIII, a 13-mer IgG-Fc domain binding peptide (IgGBP) originally identified by DeLano and co-workers...
9.
Kohli A, Kivimae S, Tiffany M, Szoka F
J Control Release
. 2014 May;
191:105-14.
PMID: 24852095
Liposomes improve the pharmacokinetics and safety of rapidly cleared drugs, but have not yet improved the clinical efficacy compared to the non-encapsulated drug. This inability to improve efficacy may be...
10.
Ruhela D, Kivimae S, Szoka F
Bioconjug Chem
. 2014 Mar;
25(4):718-23.
PMID: 24646444
Herein, we describe an efficient and high-yielding method to synthesize hyaluronan oligosaccharide-lipid conjugates. This strategy is based on first covalently attaching diphytanoyl glycerophosphatidylethanolamine (DiPhPE) to commercially available high molecular weight...